Investing News NetworkOctober 22, 2024MAVERIC-2 trial will evaluate the impact of CardiolRx(TM) following cessation of interleukin-1 blocker therapy (rilonacept or anakinra) and is expected to run concurrently with the Company's planned Phase III program.Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ('Cardiol' or the 'Company'), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, today announced plans to expand the MAVERIC clinical development program and advance CardiolRx™ into a late-stage clinical trial ('MAVERIC-2') to evaluate the impact of CardiolRx™ in recurrent pericarditis patients following cessation of interleukin-1 ('IL-1') blocker therapy.

投资新闻网2024MAVERIC-2试验将评估停止白细胞介素-1阻滞剂治疗（利洛那西普或阿那白滞素）后CardiolRx（TM）的影响，预计将与公司计划的III期计划同时进行。Cardiol Therapeutics Inc.（纳斯达克：CRDL）（TSX:CRDL）（“Cardiol”或“公司”）是一家临床阶段生命科学公司，专注于抗炎和抗纤维化治疗心脏病的研究和临床开发，今天宣布计划扩大MAVERIC临床开发计划，并将CardiolRx™推进晚期临床试验（“MAVERIC-2”），以评估CardiolRx™在停止白细胞介素-1（“IL-1”）阻滞剂治疗后对复发性心包炎患者的影响。

MAVERIC-2 is expected to be initiated during Q4 at major pericardial disease centres in the United States and Europe and to report results ahead of the Company's planned pivotal Phase III study in recurrent pericarditis.'MAVERIC-2 provides an exciting opportunity to expand the market potential for CardiolRx through the execution of a cost-effective study and potentially provides a path for an accelerated regulatory approval timeline,' said David Elsley, President & CEO of Cardiol Therapeutics.

MAVERIC-2预计将于第四季度在美国和欧洲的主要心包疾病中心启动，并在该公司计划的复发性心包炎关键III期研究之前报告结果。”Cardiol Therapeutics总裁兼首席执行官大卫·埃尔斯利（DavidElsley）说，MAVERIC-2为通过执行一项具有成本效益的研究来扩大CardiolRx的市场潜力提供了一个令人兴奋的机会，并有可能为加快监管批准时间表提供一条途径。

'This important new study, designed in collaboration with an international panel of advisors comprised of experts in pericarditis, will also augment data from our planned Phase III MAVERIC-3 trial by exploring the potential for our lead oral drug candidate to assist the growing number of recurrent pericarditis patients who seek alternative options to chronic use of immunosuppressant biologics.'MAVERIC-2 is a randomized, double-blind, placebo-controlled Phase II/III trial in approximately 110 patients.

“这项重要的新研究是与心包炎专家组成的国际顾问小组合作设计的，它还将通过探索我们的主要口服候选药物的潜力来帮助越来越多的复发性心包炎患者寻求长期使用免疫抑制剂生物制剂的替代选择，从而扩大我们计划的III期MAVERIC-3试验的数据。”MAVERIC-2是一项随机，双盲，安慰剂对照的II/III期试验，约有110名患者。

Patie.

耐心。